Ruo-Nan Duan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruo-Nan Duan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Rui-Sheng Duan
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, People’s Republic of China
1 shared publication - Tian-Yu Gao
Department of neurology, Qilu Hospital of Shandong University, Jinan, China
1 shared publication Wei-Yue Si
1 shared publication- Yiming Liu
Department of neurology, Qilu Hospital of Shandong University, Jinan, China
1 shared publication Ying Liu
1 shared publication- Yuying Zhao
Department of Neurology, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases, Research Institute of Neuromuscular and Neurodegenerative Diseases Qilu Hospital of Shandong University Jinan China
1 shared publication
Latest Publications
- 1 January 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (1) , e8-e9
Cerebral Artery Ectasia in Brucella
- 1 January 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (1) , e8-e9
Cerebral Artery Ectasia in Brucella
- Open Access
- 1 January 2025
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2025 (1)
Clinical Insights Into Anti‐Sulfatide Antibodies in Peripheral Neuropathies: A Retrospective Study
Background: Sulfatide, synthesized from glycosphingolipids via sulfation of the hydroxyl group, is a prominent lipid antigen in both the peripheral and central nervous systems. Anti‐sulfatide antibodies are detected in axonal and demyelinating neuropathies and are generally regarded as concomitant antibodies. However, their pathogenic role and precise diagnostic relevance remain unclear. Methods: This double‐center retrospective observational study tested anti‐sulfatide and antiganglioside antibodies using immunoblot assays in serum and/or cerebrospinal fluid (CSF) from patients suspected of having peripheral neuropathy. Clinical symptoms, laboratory findings, and electrophysiological results were reviewed for patients with anti‐sulfatide antibodies. Results: The most common symptoms in adult‐onset patients with anti‐sulfatide antibody included motor weakness (81.25%) and superficial sensory disturbances (68.75%). Patients with anti‐sulfatide antibodies in the CSF exhibited a higher frequency of CSF albuminocytological dissociation. Positive blood rheumatic antibodies and factors were more prevalent in seropositive patients. Electrophysiological findings revealed both axonal and demyelinating changes in these patients. Intravenous corticosteroids, immunoglobulins, and plasmapheresis proved effective treatments. Conclusions: The clinical manifestations of patients with anti‐sulfatide antibodies are highly heterogeneous. Anti‐sulfatide antibodies cause axonal and demyelinating damage in autoimmune peripheral neuropathy, presenting distinct clinical and electrophysiological features.
- 1 January 2025
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2025 (1)
Open AccessClinical Insights Into Anti‐Sulfatide Antibodies in Peripheral Neuropathies: A Retrospective Study
Background: Sulfatide, synthesized from glycosphingolipids via sulfation of the hydroxyl group, is a prominent lipid antigen in both the peripheral and central nervous systems. Anti‐sulfatide antibodies are detected in axonal and demyelinating neuropathies and are generally regarded as concomitant antibodies. However, their pathogenic role and precise diagnostic relevance remain unclear. Methods: This double‐center retrospective observational study tested anti‐sulfatide and antiganglioside antibodies using immunoblot assays in serum and/or cerebrospinal fluid (CSF) from patients suspected of having peripheral neuropathy. Clinical symptoms, laboratory findings, and electrophysiological results were reviewed for patients with anti‐sulfatide antibodies. Results: The most common symptoms in adult‐onset patients with anti‐sulfatide antibody included motor weakness (81.25%) and superficial sensory disturbances (68.75%). Patients with anti‐sulfatide antibodies in the CSF exhibited a higher frequency of CSF albuminocytological dissociation. Positive blood rheumatic antibodies and factors were more prevalent in seropositive patients. Electrophysiological findings revealed both axonal and demyelinating changes in these patients. Intravenous corticosteroids, immunoglobulins, and plasmapheresis proved effective treatments. Conclusions: The clinical manifestations of patients with anti‐sulfatide antibodies are highly heterogeneous. Anti‐sulfatide antibodies cause axonal and demyelinating damage in autoimmune peripheral neuropathy, presenting distinct clinical and electrophysiological features.